Background and Aim: Tumor cells escape host immunosurveillance and thus produce an advantageous environment for tumor progression. Recent studies have demonstrated that tumor-infiltrating lymphocytes (TILs) play a principal role in the immune response to tumors. However, little is understood about numerical alterations in CD3+ TILs during tumor progression in patients with gastric cancer. The present study examines the density of CD3+ TILs to elucidate their clinical significance in gastric cancer. Methods: The numbers of CD3+ TILs in 120 resected specimens from patients with gastric cancer and 27 endoscopic resected specimens from patients with gastric adenoma were immunohistochemically assessed using a CD3 polyclonal antibody. Results: The mean number of CD3+ TILs (±SD) in the patients with gastric cancer and adenoma was 87.5±59.8 and 379.6±128.1, respectively. Significantly more CD3+ TILs were found in specimens from patients with gastric adenoma than with gastric cancer (P<0.0001). The numbers of CD3+ TILs significantly correlated with depth of tumor invasion, lymph node metastasis, and stage (P=0.022, P=0.0004, and P=0.011, respectively). The 5-year survival rate was significantly poorer for patients with fewer CD3+ TILs (P=0.004). Multivariate analysis selected the density of CD3+ TILs as an independent prognostic factor (P=0.034). Conclusions: Our results demonstrated that the density of CD3+ TILs decreases during tumor progression. The density of CD3+ TILs is an immunological predictor of lymph node metastasis and disease outcome in patients with gastric cancer.
|Number of pages||7|
|Journal||Journal of Gastroenterology and Hepatology (Australia)|
|Publication status||Published - 07-2014|
All Science Journal Classification (ASJC) codes